title: Antimalarial activity of 77 phospholipid polar head analogs: close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth.
abstract: Seventy-seven potential analogs of phospholipid polar heads, choline and ethanolamine, were evaluated in vitro as inhibitors of Plasmodium falciparum growth. Their IC50 ranged from 10(-3) to 10(-7) mol/L. Ten compounds showed similar antimalarial activity when tested against three different parasite strains (2 chloroquine-sensitive strains and 1 chloroquine-resistant strain). Compounds showing marked antimalarial activity were assayed for their effects on phospholipid metabolism. The most active compounds (IC50 of 1 to 0.03 micromol/L) were inhibitors of de novo phosphatidylcholine (PC) biosynthesis from choline. For a series of 50 compounds, there was a close correlation between impairment of phospholipid biosynthesis and inhibition of in vitro malaria parasite growth. High choline concentrations caused a marked specific shift in the curves for PC biosynthesis inhibition. Concentrations inhibiting 50% PC metabolism from choline were in close agreement with the Ki of these compounds for the choline transporter in Plasmodium knowlesi-infected erythrocytes. By contrast, measurement of the effects of 12 of these compounds on rapidly dividing lymphoblastoid cells showed a total absence of correlation between parasite growth inhibition and human lymphoblastoid cell growth inhibition. Specific antimalarial effects of choline or ethanolamine analogs are thus likely mediated by their alteration of phospholipid metabolism. This indicates that de novo PC biosynthesis from choline is a very realistic target for new malaria chemotherapy, even against pharmacoresistant strains.
authors.affiliation: CNRS UMR 5539, Department of Biologie-Santé, Montpellier, France.
authors.forename: M L
authors.initials: ML
authors.lastname: Ancelin
authors.forename: M
authors.initials: M
authors.lastname: Calas
authors.forename: J
authors.initials: J
authors.lastname: Bompart
authors.forename: G
authors.initials: G
authors.lastname: Cordina
authors.forename: D
authors.initials: D
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Ben Bari
authors.forename: T
authors.initials: T
authors.lastname: Jei
authors.forename: P
authors.initials: P
authors.lastname: Druilhe
authors.forename: H J
authors.initials: HJ
authors.lastname: Vial
mesh_terms: D000818:Animals; D004983:Ethanolamines / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development
chemical_list: D004983:Ethanolamines; D010743:Phospholipids